Transscleral cyclophotocoagulation with micropulse laser for refractory glaucoma
This article summarizes 8 foreign research articles on the treatment of refractory glaucoma with transscleral cyclophotocoagulation with micropulse laser(MP-TSCPC).There were a total of 453 eyes with refractory glaucoma,including more than 33 eyes with pseudoexfoliative glaucoma,43 eyes with chronic angle-closure glaucoma,more than 58 eyes with neovascular glaucoma,and more than 264 eyes with primary open-angle glaucoma.Most patients had previously undergone incisional glaucoma surgery or had a history of failed glaucoma surgery.Laser power was from 1.6 to 2 W.The duration of treatment lasts between 100 to 360 seconds,and the total energy used was within range of 62 to 225 J.Follow-up time was from 2 to 18 months,and the success rate was from 33.3％to 73.7％.The preoperative highest intraocular pressure(IOP)was(39.1±13.84)mmHg,and the postoperative lowest IOP was(11.1±4.4)mmHg.The maxi-mum number of anti-glaucoma eyedrops used preoperatively was 4,while postoperatively it was reduced to a minimum of 1.5 eyedrops.Most postoperative complications were anterior chamber inflammatory reactions,with 2 cases of eyeball atrophy and 15 cases of hypotony being the most severe complications.The studies showed that MP-TSCPC can effectively reduce IOP in refractory glaucoma and is a new treatment modality for refractory glaucoma.(Int Rev Ophthalmol,2024,48:15-19)
万方数据
维普
